Dr Reddy’s Laboratories on Monday said the European Commission has granted marketing authorisation for its biosimilar to ...

The FDA has approved Osvyrti (denosumab-desu), a biosimilar to Prolia (denosumab), and Jubereq (denosumab-desu), a biosimilar to Xgeva (denosumab).

For many years, older adult patients who fractured their hip typically spent most of their recovery time with orthopedic ...

Dr Reddy’s has secured European Commission approval for AVT03, its biosimilar version of Prolia and Xgeva—medicines used to ...

Premenopausal women and men with endocrine- or medication-related risks for osteoporosis may be affected, and timely bone ...

The European Commission's approval allows Dr Reddy's to market AVT03 across the European Union and European Economic Area for ...

DelveInsight's Osteoporosis Market Insights report includes a comprehensive understanding of current treatment practices, ...

Osteoporosis can be slowed and potentially reversed through changes to smoking habits and alcohol consumption, as well as adopting healthy diet and exercise. Read more at straitstimes.com. Read more ...

CT imaging of the chest, abdomen, and spine to detect conditions such as kidney stones or pulmonary lesions can also be used ...

Accord BioPharma, Inc., the specialty division of Intas Pharmaceuticals, Ltd., focused on development of oncology, immunology ...

US FDA approves Accord BioPharma’s denosumab biosimilars Osvyrti and Jubereq: Raleigh, North Carolina Friday, November 21, 2025, 18:00 Hrs [IST] Accord BioPharma, Inc., the spec ...

Alvotech (ALVO) on Monday said that the European Commission (EC) has approved AVT03 as a biosimilar to Amgen’s Prolia and ...